Orthocell Ltd (ASX:OCC, OTC:ORHHF) has booked a milestone 2025 financial year, reporting a record revenue of $9.19 million, driven by strong sales growth across its regenerative medicine products. The company’s flagship nerve repair product, Remplir™, saw significant success in its core markets, with recent clearance from the US Food and Drug Administration teeing up further growth in the US, a key focus for the company moving forward.
For the June 2025, Orthocell delivered revenue of $2.73 million, a 22.8% increase on the previous quarter and up 45.1% from the same period in FY2024. This marks the fifth consecutive quarter of record revenue, reflecting solid traction for Remplir™, which addresses peripheral nerve injuries.
The company is on track to continue its upward trajectory, with a compounded quarterly growth rate (CQGR) of 9.5% over the last three years. Despite the strong growth, the results do not yet reflect US Remplir™ sales, which Orthocell expects to gain momentum in the first half of the 2026 financial year.
“We’ve seen excellent take-up of Remplir™ in our existing markets, most notably Australia,” Orthocell CEO Paul Anderson said. “We feel this is an endorsement of the market access model that we expect to replicate on a far larger scale in the US.”
Expanding US footprint with FDA clearance
Orthocell’s US operations received a major boost in April when Remplir™ gained US FDA 510(k) clearance, paving the way for the company to tap into the $1.6 billion US nerve repair market. It has already made progress with its US sales strategy, securing 14 specialist nerve distributors across 25 states, building the necessary infrastructure for a successful commercial launch.
Anderson noted that the company anticipated the FDA approval, and once obtained, it was able to accelerate progress towards first sales in the US.
“The key to accessing the US market is striking the right balance between internal resources and external specialist distributors who hold direct relationships with the surgeons and hospitals that are ultimately our customers,” he said.
“We couldn’t be more pleased with the progress achieved through the quarter, which culminated in the first US surgical use of Remplir at the end of June.”
Solid financial position with cash reserves
Orthocell’s cash position remains strong, with $28.6 million in the bank, up 38.8% from the previous year’s $20.6 million balance.
This financial strength provides the company with ample capital to support its expansion plans, particularly its US rollout. Notably, Orthocell’s cost-effective sales model, which leverages external distributors in global markets, minimises the need for large internal investments in the early stages of expansion.
Regulatory approvals in key international markets
In addition to its progress in the US, Orthocell secured regulatory approvals for Remplir™ in the strategically important international markets of Hong Kong, Thailand and Canada, furthering its global expansion efforts.
The company also made significant strides with its dental product Striate+™, receiving regulatory approval in Brazil, a key market in the global $735 million dental regeneration space.
With substantial cash reserves and a growing distributor network, Orthocell is strategically positioned to build on this momentum in the upcoming financial year. The company’s focus on scaling efficiently — leveraging external distributors and minimising internal capital expenditure — lays the foundation for sustainable growth, particularly as it enters the large US nerve repair market.